Soft Tissue Tenderness and Fibromyalgia Among Schizophrenia Patients.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05328518

Enrollment

286

Registered

2022-04-14

Start date

2021-06-10

Completion date

2024-09-10

Last updated

2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia, Schizophrenia

Brief summary

Numerous studies reported on comorbidity of fibromyalgia and psychiatric disorders. Approximately 30% of patients with fibromyalgia have major depression at the time of diagnosis; the lifetime prevalence of depression is 74% and that of an anxiety disorder is 60%. In some fibromyalgia patients, mood and cognitive problems are much more prominent than tenderness. From the psychiatric point of view, 49% of PTSD patients and 5% of major depression patients fulfill criteria for diagnosing fibromyalgia. The association between schizophrenia and fibromyalgia is still unknown. Study hypothesis Schizophrenia patients, who have an aberrant sensation of pain, have lower prevalence of FM compared to the general population. Primary objectives 1. Demonstrate that schizophrenia patients have lower prevalence of FM, compared to the general population. 2. To compare the self-reported extent and intensity of pain with selected tender points examination.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Women above 18 years of age. * Patients must meet DSM-5 criteria for a diagnosis of schizophrenia. * A stabled mental state. * If hospitalized, patients are scheduled for discharge on the basis of clinical assessment of psychiatric symptoms.

Exclusion criteria

* Mental co-morbidity. * Diagnosis of myofascial pain syndrome or chronic fatigue syndrome. * Alcohol or drug use. * Usage of any pain reliever medications during the week before recruitment.

Design outcomes

Primary

Measure	Time frame	Description
To compare the self-reported extent by questionnarie and intensity of pain with selected tender points examination.	1 day	To compare the self-reported extent and intensity of pain with selected tender points examination.
To compare between the degrees in pain recognition in schizophrenia patients who suffer from fibromyalgia to pain recognition in schizophrenia patients who do not suffer from fibromyalgia.	1 day	To compare between the degrees in pain recognition in schizophrenia patients who suffer from fibromyalgia to pain recognition in schizophrenia patients who do not suffer from fibromyalgia.

Countries

Israel

Outcome results